Back to search results

FORWARD Study: AlloHeme for Relapse Detection in AML/MDS Patients

This study, called FORWARD, is looking at how well a blood test named AlloHeme can predict if acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after an allogeneic hematopoietic stem cell transplant (allo-HCT). AlloHeme uses advanced technology to check for signs of your original disease in your blood. The study aims to see if AlloHeme can accurately predict relapse or other signs of disease that might lead to further treatment. You could join if you are an adult aged 18 or older with AML or MDS (including CMML) and are eligible for an allo-HCT. The study will measure how well AlloHeme performs over 12 months. The current status of this study is unclear, but it plans to enroll 400 participants.

Study design
This is an observational study, meaning researchers will watch and collect information without giving new treatments. It plans to include 400 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will evaluate AlloHeme's performance over 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07607327

Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)

Not Yet Recruiting
Not specifiedAges 18+Observational
CareDx
~400 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:AlloHeme

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate AlloHeme test performance in predicting post-transplant relapse (by FDA criteria) or any cytogenetic/molecular evidence of disease resulting in unplanned treatment intervention in AML and MDS patients.
Measured over 12 months

Conditions

AML (Acute Myelogenous Leukemia)
MDS (Myelodysplastic Syndrome)
CMML

Explore related trials

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome

Where it's being run

1 sites across 1 states
California1

Who to contact

Nishant Dwivedi, MD, PhD
[email protected]
508-981-6087
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • To evaluate AlloHeme test performance in predicting post-transplant relapse (by FDA criteria) or any cytogenetic/molecular evidence of disease resulting in unplanned treatment intervention in AML and MDS patients.12 months

    The performance of AlloHeme test in predicting post-transplant relapse (by FDA criteria) or any cytogenetic/molecular evidence of disease resulting in unplanned treatment intervention (modified FDA criteria) in patients with AML and MDS will be evaluated using: * Sensitivity * Specificity * PPV * NPV * AuROC